A Pilot Study of the OMNI 3.1 Surgical System in Subjects With Primary Open-Angle Glaucoma

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

To gain early evidence of safety and assess the effectiveness of the intraocular pressure (IOP)-lowering effectiveness of the OMNI 3.0 Surgical System in primary open-angel glaucoma (POAG).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 45
Healthy Volunteers: f
View:

• Male or female subjects, 45 years or older

• Visually significant age-related cataract and requiring phacoemulsification cataract surgery, OR, pseudophakic and a minimum of six months since cataract surgery.

• Intraocular pressure (IOP) at the Screening visit not exceeding 33 mmHg and at least 21 mmHg for unmedicated eyes or 16 mmHg if medicated (1 to 4 ocular hypotensive medications - fixed combinations count as the number of components), with a stable medication regimen for ≥2 months.

• Diagnosed with mild to moderate primary open angle glaucoma (POAG). Diagnosis must include evidence of glaucomatous optic nerve damage or visual field defect consistent with glaucomatous optic nerve damage

Locations
Other Locations
Panama
Panama Eye Center
RECRUITING
Panama City
Contact Information
Primary
Jaime Dickerson, PhD
jdickerson@sightsciences.com
+1 (817) 845-0859
Time Frame
Start Date: 2025-10-31
Estimated Completion Date: 2026-05-31
Participants
Target number of participants: 25
Treatments
Experimental: OMNI 3.0
Canaloplasty and trabeculotomy using the OMNI 3.0 surgical system, combined with phacoemulsification cataract surgery, OR as a standalone procedure in pseudophakic eyes.
Sponsors
Leads: Sight Sciences, Inc.

This content was sourced from clinicaltrials.gov